Innoviva, Inc. (INVA) — closed signal from March 10, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 8, 2026.
Predicted vs. what happened
What happened
Reached 69% of the predicted growth at its peak, without hitting the target.
The thesis — published March 10, 2026
The company looks more credible as it shifts from relying on royalties to building an infectious-disease business. Management is buying shares back and an analyst raised their price target, giving the stock several ways to move higher in the next quarter instead of depending on one big clinical result. I am cautious because trading is thin and the price recovery is still early.
Primary drivers
- Share buybacks show management confidence and reduce downside risk
- Higher analyst target makes revaluation more likely
- New infectious-disease efforts expand how the company can grow
- Several business parts lower dependence on a single trial outcome
How it played out
INVA: the target was not reached
Lyra published INVA on 2026-03-10 at $22.28 with expected growth of 14%. The thesis pointed to share buybacks, a higher analyst target, new infectious-disease efforts, and a broader business mix that lowered dependence on one trial outcome. It also noted thin trading and an early price recovery as reasons for caution.
Inside the window, INVA rose to a peak of $24.45 on 2026-04-20, a 9.7% gain. It stayed below the $25.40 target, so there were no days to target. The window ended on 2026-06-08 at $22.33. The thesis partially played out, but it did not reach the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.